Background
==========

Colon cancer is one of the most common incident cancers across Europe \[[@B1]\]. There is an urgent need for finding novel, alternative or supplementary cancer treatments. Polyunsaturated fatty acids (PUFAs) are able to inhibit growth of both colon and several other types of cancer cells *in vitro*and *in vivo*(\[[@B2]-[@B5]\] and reviewed in \[[@B6]-[@B8]\]). During the last two decades, chemical modified fatty acid (FA) analogs have been produced in an attempt to achieve FAs having increased metabolic stability and more selective and targeted effects (reviewed in \[[@B9]\]). Among these is the bioactive, saturated 3-thia FA tetradecylthioacetic acid (TTA). TTA has been shown to have both a cardioprotective effect, as well as an antiproliferative effect on cancer cells (reviewed in \[[@B10]\]). TTA has been found to inhibit growth of glioma \[[@B11],[@B12]\], leukemia \[[@B13]-[@B16]\] and colon cancer cell lines \[[@B11],[@B17]\]*in vitro*and *in vivo*, and hepatoma \[[@B18]\] and breast cancer cells \[[@B19]\]*in vitro*. TTA seems to be more potent in reducing cell growth compared with the omega-3 (n-3) PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) \[[@B20]\]. A diet containing TTA has also resulted in increased vascularisation of colon cancer xenografts in mice \[[@B17]\] and improved the survival of mice having leukemia xenografts \[[@B11],[@B14]\]. TTA food supplementation seems to be generally well tolerated by healthy persons \[[@B15],[@B21]\], and TTA therefore may have a potential in cancer treatment alone or in combination with other therapies.

The structure of TTA is equal to the saturated palmitic acid (PA), except that TTA has a sulphur atom inserted at the third position in the carbon chain \[[@B19]\]. The sulphur atom makes TTA resistant to mitochondrial β-oxidation and probably contributes substantial to its biological effects (reviewed in \[[@B10]\]). TTA is capable of reducing the growth of cancer cells that are not growth inhibited by PA \[[@B17],[@B20],[@B22]\]. TTA is degraded relatively slowly to various dicarboxylic acids via ω-oxidation and sulphur oxidation in the endoplasmic reticulum (ER) and subsequent β-oxidation in the peroxisomes. Except from blocked mitochondrial β-oxidation, the chemical properties and metabolism of TTA resembles those of normal FAs. TTA is activated by binding to coenzyme A and incorporated into various lipids, especially phospholipids (reviewed in \[[@B10],[@B23]\]).

Before any recommendations regarding use of TTA in cancer treatment can be given, it\'s important to elucidate the molecular mechanisms underlying the growth inhibitory effect of TTA. In some, but not all, cancer cells, TTA inhibits cancer cell growth via increased lipid peroxidation and oxidative stress \[[@B12]\], or partly via activation of peroxisome proliferator activated receptor gamma \[[@B22]\]. Also, TTA has been shown to induce apoptosis in several glioma \[[@B12],[@B13]\] and leukemia cell lines \[[@B13],[@B14]\]. Induction of apoptosis seems to be related to effects on mitochondria. TTA can induce a decrease in mitochondrial membrane potential \[[@B13],[@B24]\] and lead to release of cytochrome C (cyt C) and a reduction in mitochondrial glutathione, the latter indicating a selective modulation of the mitochondrial redox equilibrium \[[@B13]\]. Most of the biological effects of TTA assumed to be implicated in mediating the inhibitory effect of TTA on cancer cells do not seem to be specific for TTA, since they also are assumed to be involved in the growth inhibitory effect of other FAs like n-3 PUFAs \[[@B25]-[@B27]\].

We have previously shown that TTA inhibits the growth of SW620 human colon cancer cells *in vitro*and *in vivo*\[[@B17]\]. SW620 cell growth is also inhibited by n-3 PUFAs \[[@B2],[@B4]\]. By using gene expression analysis, we found that DHA induces extensive changes in the expression of transcripts involved in biological pathways like ER stress and unfolded protein response (UPR), protein degradation, Ca^2+^homeostasis, cell cycle progression and apoptosis \[[@B28]\]. Others have found that PA also can induce ER stress in human \[[@B29]\] and rat cancer cells \[[@B30]\].

The main functions of ER are protein synthesis and folding, lipid synthesis and maintenance of Ca^2+^homeostasis. Disruption of these processes causes accumulation of misfolded proteins in ER lumen, leading to ER stress and activation of the cellular stress response UPR. The purpose of UPR is to restore cell homeostasis and promote cell survival, but during prolonged ER stress, apoptosis may be activated. During ER stress, one of the three ER stress sensors; eukaryotic translation initiation factor 2 alpha (eIF2α) kinase 3 (EIF2AK3/PERK) is known to phosphorylate eIF2α, thereby attenuating global protein synthesis to reduce the protein load of ER. Reduced synthesis of e.g. cyclin D1 promotes cell cycle arrest, creating time to cope with the stress. However, translation of certain mRNAs is allowed, like mRNAs for activating transcription factor 4 (ATF4) and its downstream target C/EBP-homologous protein (CHOP) \[[@B31],[@B32]\]. CHOP, which is also regulated by X-box binding protein 1 (XBP-1) (reviewed in \[[@B33]\]), promotes apoptosis by down-regulating anti-apoptotic factors like B-cell lymphoma 2 (Bcl-2) \[[@B34]\] and up-regulating pro-apoptotic factors like the Bcl-2-interacting protein Bim \[[@B35]\].

During ER stress XBP-1 also activates the transcription factor CCAAT/enhancer binding protein beta (C/EBPβ) \[[@B36]\], which participates in regulation of differentiation, cell growth, cell survival and apoptosis \[[@B37],[@B38]\]. Human C/EBPβ is mainly expressed as two 46 and 42 kDa liver enriched activator protein isoforms (LAP and LAP\*) and a 20 kDa liver enriched inhibitor protein isoform (LIP) \[[@B39]\], which are synthesized from different AUG start codons within the C/EBPβ mRNA \[[@B40]\]. Since LIP lacks a transcription activation domain \[[@B41]\] and suppresses the transactivation by LAP, the LIP/LAP ratio influences on the extent of C/EBPβ-activated transcription \[[@B40]\].

LIP has been shown to decrease during early ER stress, and increase during prolonged ER stress, causing an increase in the LIP/LAP ratio \[[@B42]\]. Increased LIP seems to be essential for CHOP-induced apoptosis, since heterodimerization of LIP with CHOP promotes nuclear translocation of CHOP and pro-apoptotic gene regulation by CHOP \[[@B43]\]. In addition, CHOP-C/EBPβ \[[@B44]\] and CHOP-ATF4 \[[@B45]\] heterodimeres up-regulate the pro-apoptotic pseudo-kinase Tribbles homolog 3 (Drosophila) (TRIB3), which can promote apoptosis by inhibiting the anti-apoptotic kinase Akt \[[@B46]\] and the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) \[[@B47]\]. CHOP- and TRIB3-promoted cell death might be accompanied by the ER stress-induced caspase 4 (CASP4) and calpains \[[@B32],[@B48],[@B49]\].

In this report we have used Affymetrix gene expression analysis to search for possible molecular mechanisms underlying the growth inhibitory effect of TTA on SW620 cells *in vitro*. The results indicate that TTA reduces SW620 cell growth through activation of ER stress and UPR, by a similar mechanism as observed after treatment with DHA \[[@B28]\].

Results
=======

TTA reduces growth of SW620 cells
---------------------------------

In accordance with previous results \[[@B17]\], we verified a growth inhibitory effect of TTA (75 μM) on SW620 colon cancer cells by cell counting (data not shown) and by measuring the growth real time by using the xCELLigence System (Roche) (Figure [1A](#F1){ref-type="fig"}). The SW620 growth curve, which is presented as baseline cell index, showed that TTA (75 μM) significantly reduced the baseline cell index by 35% and 55% after 48 h and 72 h, respectively, compared to the control (Figure [1B](#F1){ref-type="fig"}).

![**Real time monitoring of TTA-induced growth inhibition of SW620 cells**. SW620 colon cancer cells were seeded in 16 well E-plates. After \~24 h, TTA (75 μM) or NaOH (control) were added. Cell growth was monitored using the xCELLigence RTCA DP Instrument (Roche). (A) SW620 cell growth presented as baseline cell index from one representative experiment. (B) Average baseline cell index (± SD) of TTA-treated cells, presented as percent of control, at indicated time points. Mean was calculated from at least two duplicate measurements in four independent experiments. \* Significantly different from control (one-tailed Student\'s t-test, P \< 0.05).](1476-511X-10-190-1){#F1}

TTA induces extensive changes at mRNA level indicating ER stress and UPR
------------------------------------------------------------------------

In an attempt to unravel the mechanisms underlying the growth-inhibiting effect of TTA, SW620 cells were cultivated in the absence or presence of 75 μM TTA for 24 h, followed by gene expression profiling. Differentially expressed transcripts are presented and listed by full and short names in Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}.

###### 

Gene expression results

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene Symbol                                                                                         Affymetrix ID    Refseq NCBI ID   Transcript name                                                                                  SW620\
                                                                                                                                                                                                                                         Fold Change
  --------------------------------------------------------------------------------------------------- ---------------- ---------------- ------------------------------------------------------------------------------------------------ -------------
  **ER stress and unfolded protein response**                                                                                                                                                                                            

                                                                                                                                                                                                                                         

  ATF3                                                                                                202672_s\_at     NM_001030287\    Activating transcription factor 3                                                                3.5
                                                                                                                       NM_001040619\                                                                                                     
                                                                                                                       NM_001674\                                                                                                        
                                                                                                                       NM_004024                                                                                                         

                                                                                                                                                                                                                                         

  ATF4                                                                                                200779_at        NM_001675\       Activating transcription factor 4                                                                1.7
                                                                                                                       NM_182810                                                                                                         

                                                                                                                                                                                                                                         

  ATF6                                                                                                217550_at\       NM_007348        Activating transcription factor 6                                                                1.5\
                                                                                                      231927_at\                                                                                                                         1.3\
                                                                                                      203952_at                                                                                                                          1.2

                                                                                                                                                                                                                                         

  CEBPB                                                                                               212501_at        NM_005194        CCAAT/enhancer binding protein (C/EBP), beta                                                     3.2

                                                                                                                                                                                                                                         

  CHOP/DDIT3                                                                                          209383_at        NM_001130101\    DNA-damage-inducible transcript 3                                                                2.7
                                                                                                                       NM_001130102\                                                                                                     
                                                                                                                       NM_004083\                                                                                                        
                                                                                                                       NM_005693                                                                                                         

                                                                                                                                                                                                                                         

  GADD34                                                                                              37028_at\        NM_014330        Growth arrest and DNA-damage-inducible 34                                                        2.0\
                                                                                                      202014_at                                                                                                                          2.0

                                                                                                                                                                                                                                         

  IRE1/ERN1                                                                                           235745_at        NM_001433        Inositol-requiring enzyme 1/Endoplasmic reticulum to nucleus signaling 1                         1.7

                                                                                                                                                                                                                                         

  NRF2/NFE2L2                                                                                         201146_at        NM_001145412\    Nuclear factor (erythroid-derived 2)-like 2                                                      1.3
                                                                                                                       NM_001145413\                                                                                                     
                                                                                                                       NM_006164                                                                                                         

                                                                                                                                                                                                                                         

  TRIB3                                                                                               1555788_a\_at\   NM_021158        Tribbles homolog 3 (Drosophila)                                                                  5.1\
                                                                                                      218145_at                                                                                                                          4.9

                                                                                                                                                                                                                                         

  XBP1                                                                                                242021_at\       NM_001079539\    X-box binding protein 1                                                                          1.2\
                                                                                                      200670_at        NM_005080                                                                                                         1.6

                                                                                                                                                                                                                                         

  **Chaperones/Protein folding/Unfolded protein response/Protein degradation/Amino acid synthesis**                                                                                                                                      

                                                                                                                                                                                                                                         

  ASNS                                                                                                205047_s\_at     NM_001673\       Asparagine synthetase                                                                            4.8
                                                                                                                       NM_133436\                                                                                                        
                                                                                                                       NM_183356                                                                                                         

                                                                                                                                                                                                                                         

  CREB3L2                                                                                             212345_s\_at     NM_194071        cAMP responsive element binding protein 3-like 2                                                 1.4

                                                                                                                                                                                                                                         

  CREB3L3                                                                                             234361_at        NM_032607        cAMP responsive element binding protein 3-like 3                                                 3.0

                                                                                                                                                                                                                                         

  DNAJB2                                                                                              202500_at        NM_001039550\    DnaJ (Hsp40) homolog, subfamily B, member B2                                                     1.3
                                                                                                                       NM_006736                                                                                                         

                                                                                                                                                                                                                                         

  DNAJB14                                                                                             222850_s\_at     NM_001031723     DnaJ (Hsp40) homolog, subfamily B, member B14                                                    1.2

                                                                                                                                                                                                                                         

  DNAJC24                                                                                             242562_at        NM_181706        DnaJ (Hsp40) homolog, subfamily C, member 24                                                     1.4

                                                                                                                                                                                                                                         

  EDEM1                                                                                               203279_at        NM_014674        ER degradation enhancer, mannosidase alpha-like 1                                                1.3

                                                                                                                                                                                                                                         

  EDEM3                                                                                               220342_x\_at     NM_025191        ER degradation enhancer, mannosidase alpha-like 3                                                1.2

                                                                                                                                                                                                                                         

  ERO1LB                                                                                              231944_at        NM_019891        ERO1-like beta (S. cerevisiae)                                                                   1.3

                                                                                                                                                                                                                                         

  HMOX1/HSP32                                                                                         203665_at        NM_002133        Heme oxygenase (decycling) 1                                                                     1.6

                                                                                                                                                                                                                                         

  HSPA13                                                                                              202557_at\       NM_006948        Heat shock 70kDa protein 13                                                                      1.4\
                                                                                                      202558_s\_at                                                                                                                       1.7

                                                                                                                                                                                                                                         

  PDIA2                                                                                               206691_s\_at     NM_006849        Protein disulfide isomerase family A, member 2                                                   1.2

                                                                                                                                                                                                                                         

  PFDN2                                                                                               218336_at        NM_012394        Prefoldin 2                                                                                      1.4

                                                                                                                                                                                                                                         

  PSMB1                                                                                               214289_at        NM_002793        Proteasome subunit, beta type, 1                                                                 1.3

                                                                                                                                                                                                                                         

  SQSTM1                                                                                              201471_s\_at\    NM_001142298\    Sequestosome 1                                                                                   2.1\
                                                                                                      213112_s\_at\    NM_001142299\                                                                                                     3.1\
                                                                                                      239004_at\       NM_003900                                                                                                         1.3\
                                                                                                      244804_at                                                                                                                          2.1

                                                                                                                                                                                                                                         

  UBE2B                                                                                               239163_at        NM_003337        Ubiquitin-conjugating enzyme E2B (RAD6 homolog)                                                  1.5

                                                                                                                                                                                                                                         

  SEC61A2                                                                                             219499_at\       NM_001142627\    Sec61 alpha 2 subunit (S. cerevisiae)                                                            1.3\
                                                                                                      228747_at        NM_001142628\                                                                                                     1.2
                                                                                                                       NM_018144                                                                                                         

                                                                                                                                                                                                                                         

  SEC61B                                                                                              244700_at        NM_006808        Sec61 beta subunit                                                                               1.6

                                                                                                                                                                                                                                         

  SEC63                                                                                               201914_s\_at\    NM_007214        SEC63 homolog (S. cerevisiae)                                                                    1.3\
                                                                                                      201915_s\_at\                                                                                                                      1.2\
                                                                                                      201916_s\_at                                                                                                                       1.3

                                                                                                                                                                                                                                         

  **Ca2^+^homeostasis, signaling and transport**                                                                                                                                                                                         

                                                                                                                                                                                                                                         

  ATP2B4/PMCA4                                                                                        205410_s\_at\    NM_001001396\    ATPase, Ca^2+^transporting, plasma membrane 4                                                    1.5\
                                                                                                      212135_s\_at\    NM_001684                                                                                                         2.7\
                                                                                                      212136_at                                                                                                                          5.4

                                                                                                                                                                                                                                         

  CAPN1                                                                                               232012_at        NM_005186        Calpain 1, (mu/I) large subunit                                                                  1.4

                                                                                                                                                                                                                                         

  CAPN2                                                                                               208683_at\       NM_001146068\    Calpain 2, large subunit                                                                         1.4\
                                                                                                      214888_at        NM_001748                                                                                                         1.8

                                                                                                                                                                                                                                         

  CAPN5                                                                                               205166_at        NM_004055        Calpain 5                                                                                        1.4

                                                                                                                                                                                                                                         

  HERPUD1                                                                                             217168_s\_at     NM_001010989\    Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1   1.9
                                                                                                                       NM_001010990\                                                                                                     
                                                                                                                       NM_014685                                                                                                         

                                                                                                                                                                                                                                         

  ITPR1                                                                                               244090_at        \-\--            Inositol 1,4,5-triphosphate receptor, type 1                                                     1.3

                                                                                                                                                                                                                                         

  ITPR3                                                                                               201187_s\_at\    NM_002224        Inositol 1,4,5-triphosphate receptor, type 3                                                     1.3\
                                                                                                      201188_s\_at\                                                                                                                      1.5\
                                                                                                      201189_s\_at                                                                                                                       1.5

                                                                                                                                                                                                                                         

  PLCD3                                                                                               234971_x\_at\    NM_133373        Phospholipase C, delta 3                                                                         1.3\
                                                                                                      1552476_s\_at                                                                                                                      1.3

                                                                                                                                                                                                                                         

  S100A10                                                                                             200872_at\       NM_002966        S100 calcium binding protein A10                                                                 1.2\
                                                                                                      238909_at                                                                                                                          2.4

                                                                                                                                                                                                                                         

  S100P                                                                                               204351_at        NM_005980        S100 calcium binding protein P                                                                   4.9

                                                                                                                                                                                                                                         

  STC2                                                                                                203438_at\       NM_003714        Stanniocalcin 2                                                                                  2.1\
                                                                                                      203439_s\_at                                                                                                                       2.7

                                                                                                                                                                                                                                         

  **Cell cycle/Apoptosis**                                                                                                                                                                                                               

                                                                                                                                                                                                                                         

  ATF5                                                                                                204998_s\_at\    NM_012068        Activating transcription factor 5                                                                1.5\
                                                                                                      204999_s\_at                                                                                                                       1.7

                                                                                                                                                                                                                                         

  AURKA                                                                                               208080_at        NM_003600\       Aurora kinase A                                                                                  -1.3
                                                                                                                       NM_198433\                                                                                                        
                                                                                                                       NM_198434\                                                                                                        
                                                                                                                       NM_198435\                                                                                                        
                                                                                                                       NM_198436\                                                                                                        
                                                                                                                       NM_198437                                                                                                         

                                                                                                                                                                                                                                         

  BIRC5                                                                                               202094_at\       NM_001012270\    Baculoviral IAP repeat-containing 5/Survivin                                                     -1.7\
                                                                                                      202095_s\_at\    NM_001012271\                                                                                                     -1.3\
                                                                                                      210334_x\_at     NM_001168                                                                                                         -1.3

                                                                                                                                                                                                                                         

  CASP4                                                                                               213596_at        NM_001225\       Caspase 4                                                                                        1.4
                                                                                                                       NM_033306                                                                                                         

                                                                                                                                                                                                                                         

  CCNA2                                                                                               203418_at\       NM_001237        Cyclin A2                                                                                        -1.2\
                                                                                                      213226_at                                                                                                                          -1.2

                                                                                                                                                                                                                                         

  CCND3                                                                                               201700_at        NM_001136017\    Cyclin D3                                                                                        -2.0
                                                                                                                       NM_001136125\                                                                                                     
                                                                                                                       NM_001136126\                                                                                                     
                                                                                                                       NM_001760                                                                                                         

                                                                                                                                                                                                                                         

  CCNE1                                                                                               213523_at        NM_001238\       Cyclin E1                                                                                        -1.3
                                                                                                                       NM_057182                                                                                                         

                                                                                                                                                                                                                                         

  CCNE2                                                                                               205034_at\       NM_057749        Cyclin E2                                                                                        -2.9\
                                                                                                      211814_s\_at                                                                                                                       -3.1

                                                                                                                                                                                                                                         

  CCNF                                                                                                204827_s\_at     NM_001761        Cyclin F                                                                                         -1.2

                                                                                                                                                                                                                                         

  CDC2/CDK1                                                                                           203214_x\_at     NM_001130829\    Cell division cycle 2, G1 to S and G2 to M                                                       -1.2
                                                                                                                       NM_001786\                                                                                                        
                                                                                                                       NM_033379                                                                                                         

                                                                                                                                                                                                                                         

  CDK2                                                                                                204252_at\       NM_001798\       Cyclin-dependent kinase 2                                                                        -1.3\
                                                                                                      211804_s\_at     NM_052827                                                                                                         -1.4

                                                                                                                                                                                                                                         

  CDK4                                                                                                202246_s\_at     NM_000075        Cyclin-dependent kinase 4                                                                        -1.4

                                                                                                                                                                                                                                         

  CDK5                                                                                                204247_s\_at     NM_001164410\    Cyclin-dependent kinase 5                                                                        -1.5
                                                                                                                       NM_004935                                                                                                         

                                                                                                                                                                                                                                         

  CDK6                                                                                                224847_at\       NM_001145306\    Cyclin-dependent kinase 6                                                                        -1.4\
                                                                                                      224848_at\       NM_001259                                                                                                         -1.5\
                                                                                                      224851_at\                                                                                                                         -1.3\
                                                                                                      243000_at                                                                                                                          -1.3

                                                                                                                                                                                                                                         

  CDKN2A                                                                                              211156_at        NM_000077\       Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)                              1.3
                                                                                                                       NM_058195\                                                                                                        
                                                                                                                       NM_058197                                                                                                         

                                                                                                                                                                                                                                         

  CDKN2B                                                                                              207530_s\_at\    NM_004936\       Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)                                        1.5\
                                                                                                      236313_at        NM_078487                                                                                                         2.0

                                                                                                                                                                                                                                         

  CDKN2D                                                                                              210240_s\_at     NM_001800\       Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)                                        1.2
                                                                                                                       NM_079421                                                                                                         

                                                                                                                                                                                                                                         

  CUL1                                                                                                238509_at        NM_003592        Cullin 1                                                                                         1.4

                                                                                                                                                                                                                                         

  KLF4                                                                                                220266_s\_at\    NM_004235        Kruppel-like factor 4 (gut)                                                                      1.9\
                                                                                                      221841_s\_at                                                                                                                       2.4

                                                                                                                                                                                                                                         

  PDCD4                                                                                               202731_at\       NM_014456\       Programmed cell death 4 (neoplastic transformation inhibitor)                                    1.3\
                                                                                                      212593_s\_at     NM_145341                                                                                                         1.3

                                                                                                                                                                                                                                         

  PDCD6                                                                                               222152_at\       NM_013232        Programmed cell death 6                                                                          1.3\
                                                                                                      222380_s\_at                                                                                                                       1.3

                                                                                                                                                                                                                                         

  SFN                                                                                                 33322_i\_at\     NM_006142        Stratifin                                                                                        1.6\
                                                                                                      33323_r\_at\                                                                                                                       1.7\
                                                                                                      209260_at                                                                                                                          1.6
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Significantly differentially expressed transcripts in SW620 treated with TTA (75 μM) for 24 h as determined by Affymetrix microarray analysis (P \< 0.05).

After incubation with TTA, the transcription level of several genes involved in ER stress and UPR were affected. The ER stress sensors inositol-requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6), and downstream targets of these, like XBP-1, were up-regulated (Table [1](#T1){ref-type="table"}). However, most changes in the ER stress signaling pathway were found downstream of PERK. Phosphorylation of eIF2α by PERK is a hallmark of ER stress (reviewed in \[[@B31]\]). After TTA treatment, phosphorylated eIF2α (eIF2α-P) was found significantly increased after 6 h and 24 h (Figure [2A](#F2){ref-type="fig"}).

![**TTA induces proteins involved in ER stress and UPR**. SW620 cells were treated with TTA (75 μM) or NaOH (control) for indicated time periods, and proteins were quantified by western blotting. (A) Analysis of eIF2α-P and Cyclin D1 from cytosolic protein extracts and ATF4 and CHOP from nuclear protein extracts. (B) Analysis of TRIB3 and the C/EBPβ protein isoforms LAP (45 kDa) and LIP (20 kDa) from nuclear protein extracts. Blots were quantified, and band intensities normalized relative to the respective loading control; β-actin (Cyclin D1), Lamin (nuclear extracts) or total level of eIF2α (eIF2α-P), to adjust for unequal protein loading within the membranes. Band intensities were related to the 24 h control band to adjust for differences in signal intensities between the membranes, except for TRIB3 where the band intensities are related to the 24 h TTA band (not expressed in control). Quantified results show mean fold change (± SD) of TTA-samples relative to control at indicated time periods for three independent experiments. One representative blot is shown. \* Significantly different from control (one-tailed Student\'s t-test, P \< 0.05).](1476-511X-10-190-2){#F2}

Phosphorylation of eIF2α induces transcription of ATF4 and its downstream targets, like ATF3, CHOP, growth arrest and DNA-damage-inducible 34 (GADD34), TRIB3 \[[@B50],[@B51]\] and heme oxygenase 1 (HMOX1) \[[@B52]\]. All these transcripts were up-regulated upon TTA treatment (Table [1](#T1){ref-type="table"}). Moreover, the protein levels of ATF4, CHOP (Figure [2A](#F2){ref-type="fig"}) and TRIB3 (Figure [2B](#F2){ref-type="fig"}) were also increased. ATF4 is known to induce genes involved in amino acid synthesis, and several transcripts involved in amino acid synthesis and transport were also up-regulated (Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}).

When UPR is activated, cells try to up-regulate the folding capacity e.g. through up-regulation of chaperones and heat shock proteins (Hsps) \[[@B31]\]. Transcripts of the folding machinery were found to be up-regulated in the SW620 cells after incubation with TTA. These include prefoldin 2 (PFDN2), DnaJ (HSP40) homolog, subfamily B, member 2 (DNAJB2), DNAJB14, DnaJ (Hsp40) homolog, subfamily C, member 24 (DNAJC24), heat shock protein 13 (HSPA13), HSP32 (HMOX1) and hypoxia up-regulated 1 (HYOU1) (Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}). Protein disulfide isomerase family A, member 2 (PDIA2) and ERO1-like beta (ERO1LB), which are known to catalyze protein folding \[[@B31],[@B53]\], were also up-regulated (Table [1](#T1){ref-type="table"}). However, some DnaJ (Hsp40) homolog subfamily members and Hsps were also found to be down-regulated (Additional file [1](#S1){ref-type="supplementary-material"}).

During ER stress, improperly folded proteins are transferred to ER degradation enhancer, mannosidase alpha-like protein (EDEM) and translocated to cytosol for proteasomal degradation; a process called ER associated degradation (ERAD) \[[@B31]\]. EDEM1 and EDEM3, in addition to several proteasomal subunits and ubiquitin-related transcripts, were up-regulated upon TTA treatment. Also, proteasome subunit, beta type, 1 (PSMB1), ubiquitin-conjugating enzyme E2B (RAD6 homolog) (UBE2B) and cullin1 (CUL1) were up-regulated (Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}). In addition, TTA also up-regulated sequestosome 1 (SQSTM1), which is able to sequester and shuttle polyubiquitinated, misfolded proteins to the proteasome (reviewed in \[[@B54]\]) (Table [1](#T1){ref-type="table"}). Moreover, TTA up-regulated transcripts for parts of the ER translocation machinery which transports proteins to the cytosol, like Sec61 alpha 2 subunit (SEC61A2), Sec61 beta subunit (SEC61B) and SEC63 homolog (SEC63) (Table [1](#T1){ref-type="table"}).

TTA affects Ca^2+^homeostasis
-----------------------------

Another indication of an ER stress condition in SW620 cells treated with TTA is the altered expression of transcripts coding for proteins involved in Ca^2+^homeostasis. The more than 5-fold up-regulation of ATPase, Ca^2+^-transporting, plasma membrane 4 (ATP2B4/PMCA4) might indicate the presence of a high Ca^2+^concentration in the cytosol (Table [1](#T1){ref-type="table"}). A possible high Ca^2+^level in the cytosol may be part of the ER stress response, with Ca^2+^leaking from ER through the up-regulated IP3 receptors, type 1 and 3 (ITPR1 and 3, Table [1](#T1){ref-type="table"}). We also found Phospholipase C D3 (PLCD3), which is known to participate in the generation of IP3 \[[@B55]\], to be up-regulated at mRNA level after TTA-treatment (Table [1](#T1){ref-type="table"}).

Among other important Ca^2+^-related transcripts, we found several S100 Ca^2+^binding proteins to be differentially expressed after TTA-treatment, e.g. S100P and S100A10 were up-regulated (Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}). Also, TTA caused up-regulation of Stanniocalcin 2 (STC2), which is induced downstream of PERK and critical for survival after UPR \[[@B56]\]. TTA further up-regulated homocysteine-inducible endoplasmic reticulum stress-inducible ubiquitin-like domain member 1 (HERPUD1) (Table [1](#T1){ref-type="table"}), which is known to counteract Ca^2+^disturbances during ER stress \[[@B57]\].

Effect of TTA on cell cycle
---------------------------

TTA affected the mRNA level of several cell cycle transcripts, most of them having rather small fold change values. Positive cell cycle regulators were down-regulated and negative regulators were up-regulated, as outlined below.

The cell cycle is known to be positively regulated by cyclins (CCNs) and cyclin dependent kinases (CDKs). The mRNA level of cyclin D3 (CCND3), but not cyclin D1, was down-regulated upon TTA treatment (Table [1](#T1){ref-type="table"}). However, the protein level of cyclin D1 was significantly decreased after incubation with TTA (Figure [2A](#F2){ref-type="fig"}). Moreover, transcripts for CCNA2, CCNE1, CCNE2, CCNF, CDK1/CDC2, CDK2, CDK4, CDK5 and CDK6 were down-regulated (Table [1](#T1){ref-type="table"}), indicating inhibition of cell cycle progression. The CDK4 inhibitors CDK inhibitor 2A (CDKN2A), CDKN2B and CKDN2D, which are negative regulators of cell cycle, were increased (Table [1](#T1){ref-type="table"}). In addition, the tumor suppressor programmed cell death 4 (PDCD4), which is able to reduce the protein level of CDK4 \[[@B58]\], and PDCD6 were up-regulated (Table [1](#T1){ref-type="table"}).

Other important cell cycle related transcripts that were up-regulated by TTA were ATF5, stratifin (SFN/14-3-3 sigma) and kruppel like factor 4 (KLF4) (Table [1](#T1){ref-type="table"}). TTA also induced down-regulation of aurora kinase A (AURKA) and survivin/baculoviral IAP repeat-containing 5 (BIRC5) (Table [1](#T1){ref-type="table"}).

TTA changes expression of transcripts involved in ER stress-related apoptosis
-----------------------------------------------------------------------------

Transcripts related to ER stress-induced apoptosis were also up-regulated upon TTA treatment. In addition to the up-regulation of CHOP and TRIB3, TTA also increased transcription of CASP4, calpain 1, large subunit (CAPN1), CAPN2 and CAPN5 (Table [1](#T1){ref-type="table"}).

The C/EBPβ LIP isoform is known to augment ER stress-induced cell death by interfering with the expression of TRIB3 \[[@B59]\]. C/EBPβ (CEBPB) was up-regulated 3.2-fold at mRNA level (Table [1](#T1){ref-type="table"}) after TTA treatment. Western blotting mainly displayed two C/EBPβ isoforms; a highly expressed 45 kDa LAP isoform and a lower expressed 20 kDa LIP isoform. The 42 kDa LAP\* isoform was only found in very low amounts (Figure [2B](#F2){ref-type="fig"}). TTA did not affect the level of LAP, but induced a significant 6.9- and 11.2-fold induction of LIP after 24 and 48 h, respectively (Figure [2B](#F2){ref-type="fig"}). The accumulation of LIP at these time points caused a significant 6.6- and 13.3-fold increase in the LIP/LAP ratio after 24 h and 48 h, respectively, compared to control cells.

During ER stress, cAMP responsive element binding protein 3-like 2 and 3 (CREB3L2 and CREB3L3) are induced in order to attenuate ER stress-induced cell death \[[@B60]\]. These transcripts were also up-regulated (Additional file [1](#S1){ref-type="supplementary-material"}).

Discussion
==========

Several studies have shown that TTA inhibits the growth of various cancer cells *in vitro*and *in vivo*\[[@B13],[@B20],[@B22]\]. We have previously shown that TTA inhibits DNA synthesis in SW620 human colon cancer cells in a time- and dose-dependent manner \[[@B17]\], and the growth inhibitory effect of TTA on this cell line was confirmed in the current study by xCELLigence proliferation assay. This assay monitors cell growth real time by measuring changes in electric impedance between two golden electrodes embedded in the bottom of the cell culture wells. The impedance, which is converted to a cell index value, is directly proportional to the number of cells and also reflects the cells\' viability, morphology and adhesion strength \[[@B61]\]. The baseline cell index declined compared to the control from approximately 20 hours after TTA-supplementation. Previous studies have indicated that TTA affects multiple biochemical pathways that might play a role in its growth-limiting effect on different cancer cells. However, the exact mechanisms are not yet clear.

This is the first study demonstrating that TTA is able to induce ER stress in cancer cells. Transcripts involved in ER stress and downstream of all three ER stress sensors, like ATF6, IRE1, XBP-1 and ATF4, were found to be differentially expressed after treating SW620 cells with TTA. Also, the increased expression of Hsps and DNAJs indicates that the cells try to increase their protein folding capacity. The up-regulation of EDEM1 and EDEM3, SQSTM1, proteasomal subunits and ubiquitin-related transcripts indicates activation of ERAD.

The PERK branch of UPR was found to be activated, supported by the increased protein level of eIF2α-P and ATF4, as well as up-regulation of several downstream targets of ATF4, like ATF3, ASNS, CHOP and TRIB3, at mRNA level. CHOP and TRIB3, also induced at protein level, are known to link ER stress to ER stress-induced cell death (reviewed in \[[@B32]\]). The enhanced level of these proteins and transcripts for CASP4 and calpains indicates that TTA causes prolonged ER stress and direct the cell fate towards induction of death. We have previously shown that DHA induces ER stress with increased eIF2α-P, ATF4 and CHOP in the same cell line \[[@B28],[@B62]\]. We also found HL-60 leukemia cells to induce ER stress upon EPA treatment \[[@B63]\].

In SW620 cells, TTA up-regulated the C/EBPβ LIP isomer, while LAP was unchanged. LIP is capable of modulating the ER stress response by augmenting cell death, e.g. by enhancing the activity of CHOP \[[@B43]\]. On the contrary, LAP may attenuate ER stress and ER stress induced cell death by inhibiting CHOP \[[@B59],[@B64]\]. However, Li *et al*. found that LAP modulated the ER stress response by enhancing the expression of pro-apoptotic genes. They also proposed that the ER stress response may be modulated by regulation of the LIP/LAP ratio \[[@B42]\]. We found this ratio to be increased after 24 and 48 h of TTA treatment, supporting the assumption that TTA causes prolonged ER stress and a switch towards induction of cell death. Even if C/EBPβ mRNA was up-regulated, we only found an increase of LIP at protein level. Different regulation of LIP and LAP might be explained by different synthesis and degradation rates of these isomers \[[@B42]\].

Our results also indicate that TTA affects several transcripts involved in cell cycle progression. Transcripts involved in regulation of both the G1/S and G2/M phases were differentially expressed. In general, positive cell cycle regulators (like CDKs, cyclins, AURKA and survivin) were down-regulated, and negative cell cycle regulators (like ATF5, SFN and KLF4) were up-regulated, which indicates a stop in the cell cycle progression. We have previously demonstrated that DHA treatment of the SW620 cells affects several cell cycle transcripts and proteins like CDKs, cyclins and survivin etc. \[[@B62]\] and arrests the cells in the G2/M phase of the cell cycle \[[@B2]\]. Brewer *et. al*. stated that cell cycle arrest might be induced during ER stress to prevent cells from completing cell division when the conditions are compromising proper folding and assembly of proteins \[[@B65]\].

TTA also seems to induce changes in expression of transcripts involved in maintenance of Ca^2+^homeostasis. The ER lumen contains a high Ca^2+^concentration, and induction of ER stress may either come from and/or culminate with a release of Ca^2+^from the ER (reviewed in \[[@B66],[@B67]\]). ER stress-accompanied changes in the Ca^2+^metabolism may lead to a pro-apoptotic signal via the mitochondria \[[@B66]\]. We have previously shown that DHA and EPA affect Ca^2+^homeostasis in cancer cells \[[@B28],[@B63]\]. Apoptosis has been observed in other cancer cells treated with TTA \[[@B13],[@B22]\], and it has been proposed that this effect is mediated via mitochondrial alterations, such as decrease in mitochondrial membrane potential and release of Cyt C \[[@B13]\]. CHOP and C/EBPβ may be involved in the regulation of mitochondrial stress genes like TRIB3 \[[@B44]\] in response to accumulation of unfolded proteins in mitochondria \[[@B68]\]. Their up-regulation by TTA may indicate that the SW620 cells are undergoing a mitochondrial stress after TTA treatment.

Madsen *et al*. found TTA to be incorporated mainly into phospholipids in liver after TTA supplementation to rats \[[@B69]\]. The inner mitochondrial membrane phospholipid cardiolipin (CL) is essential for the function of several mitochondrial protein complexes. It interacts with mitochondrial Cyt C, which might utilize reactive oxygen species and cause oxidation of CL. Oxidized CL is required for release of pro-apoptotic factors like Cyt C to cytosol \[[@B70]\]. Enrichment of EPA and DHA in CL isolated from colonic mucosa in rats fed fish oil or EPA/DHA ethyl esters might result in high susceptibility to lipid peroxidation due to the FAs\' high degree of unsaturation. This may trigger release of pro-apoptotic factors from mitochondria (reviewed in \[[@B71]\]). Decreased synthesis of CL has also been related to Cyt C release from mitochondria during PA-induced apoptosis (reviewed in \[[@B9]\]). It remains to be investigated if this is the case with TTA.

Conclusions
===========

TTA induces extensive changes in the expression of genes involved in several biological pathways. TTA causes accumulation of misfolded proteins in ER, causing ER stress and activation of UPR. The results show that TTA inhibits SW620 cell growth, at least partly, via the same mechanisms as DHA. Thus, cancer cells seem to cope with stress induced by various FAs through the same mechanisms.

Methods
=======

Materials and cell culture
--------------------------

TTA was prepared at the Department of Chemistry, University of Bergen, Norway, as described previously \[[@B72]\] and in Supplementary experimental procedures (Additional file [2](#S2){ref-type="supplementary-material"}). All other solvents were of reagent grade from commercial sources. Antibody specifications are found in Additional file [2](#S2){ref-type="supplementary-material"}. The human colon carcinoma cell line SW620 was obtained from the American Type Culture Collection (ATCC, Rockville, MD) and cultivated in Leibovitz\'s L-15 medium (Cambrex, BioWhittaker, Walkersville, MD) supplemented with L-glutamine (2 mM), FBS (10%) and gentamicin (45 mg/l) (complete growth medium), in a humidified atmosphere of 5% CO~2~: 95% air at 37°C.

Cell proliferation assay by xCELLigence
---------------------------------------

SW620 cells were seeded in 16 well plates (E-plate 16, Roche, Mannheim, Germany) (12.000 cells in 150 μl medium/well), following the xCELLigence Real Time Cell Analyzer (RTCA) DP instrument manual as provided by the manufacturer (Roche). After \~24 h, TTA (75 μM, prepared as described in Additional file [2](#S2){ref-type="supplementary-material"}) or the vehicle NaOH (control medium) was added, and the experiment was allowed to run for 72 h. Average baseline cell index and percent reduction of baseline cell index for TTA-treated cells compared to control cells were calculated for at least two measurements from 4 replicate experiments ± SD. Significance was calculated using one-tailed Student\'s t-test (P \< 0.05).

RNA isolation, gene expression profiling and statistical analysis
-----------------------------------------------------------------

SW620 cells were seeded in 175 cm^2^flasks (3.5 × 10^6^cells in 28 ml medium). After 24 h incubation, cells were treated with TTA (75 μM) or NaOH (control) for 24 h. Cell harvesting and total RNA isolation was performed as elaborated in \[[@B28]\], using the High Pure RNA Isolation Kit (Roche). Gene expression profiling was performed following the Eukaryote expression manual from Affymetrix (Santa Clara, CA), using the Human Genome U133 2.0 Plus Array (Affymetrix), as described in Additional file [2](#S2){ref-type="supplementary-material"}. Statistical analysis of gene expression results was performed using the RMA method. Differentially expressed genes were identified using a linear model with a modified T-statistic \[[@B73]\], and results were corrected for multiple testing using the method described in \[[@B74]\] with a false discovery rate of 0.05. Annotations of probe sets and biological information of genes were retrieved from the web-based NetAffx Analysis Center at <affymetrix.com> and eGOn at genetools.no. Signal values presented are mean values of 3 replicate experiments. All experiments have been submitted to Array-Express with accession number E-MEXP-2590.

Western blot analysis
---------------------

Cells were treated with TTA (75 μM) or NaOH for 3, 6, 12, 24 and/or 48 h, as described in the gene expression profiling method. For detection of eIF2α-P and cyclin D1, cells were harvested as elaborated in \[[@B28]\], and cytosolic protein extracts were prepared immediately in lysis buffer as described in \[[@B63]\]. Nuclear protein extracts for detection of ATF4, CHOP, TRIB3 and C/EBPβ were obtained by using Nuclear Extract Kit (Active Motif, Rixensart, Belgium) according to the manufacturer\'s protocol. Protein concentrations were measured using Bio-Rad Protein Assay (Bio-Rad, Hercules, CA), and the protein extracts were snap-freezed in liquid nitrogen and stored at -80°C until further use. Cytosolic and nuclear proteins (80 or 50 μg per well, respectively) were separated on 10% precast denaturing NuPAGE^®^gels (Invitrogen, Carlsbad, US) and transferred onto Immobilon polyvinylidene difluoride membranes (Millipore, Billerica, MA). Membranes were blocked in phosphate buffered saline buffer with 0.1% (v/v) Tween^®^20 (BioRad, Hercules, CA) and 5% blocker non-fat dry milk, before incubated with primary and secondary horse radish peroxidase-conjugated antibodies (DAKO, Carpinteria, CA) dissolved in this blocking buffer as described in Additional file [2](#S2){ref-type="supplementary-material"}. eIF2α-P incubations were performed using tris-buffered saline Tween 20 buffer as described in \[[@B63]\]. Blots were detected by chemiluminescense using SuperSignal^®^West Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL) and visualized by Kodak Image Station 4000R (Eastman Kodak Co., Rochester, NY). Western blot band intensities were quantified using Kodak Molecular Imaging Software (version 4.0.1). Quantified western blot results, based on 3 independent replicates, were analysed as described in the proliferation assay method.

List of abbreviations
=====================

Transcript short names are to be found in Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}.

Cyt C: Cytochrome C; DHA: Docosahexaenoic acid; eIF2α: Eukaryote translation initiation factor 2 alpha; EIF2AK3/PERK: eIF2α kinase 3; eIF2α-P: phoshorylated eIF2α; EPA: Eicosapentaenoic acid; ER: Endoplasmic reticulum; ERAD: ER-associated degradation; FAs: Fatty acids; Hsps: Heat shock proteins; LAP: Liver enriched activator protein; LIP: Liver enriched inhibitor protein; n-3: Omega-3; PA: Palmitic acid; PUFAs: Polyunsaturated fatty acids; TTA: Tetradecylthioacetic acid; UPR: Unfolded protein response
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###### Additional file 1

**Supplementary gene expression results**. Functional categories of significantly differentially expressed transcripts affected in SW620 cells treated with TTA (75 μM) for 24 h, as determined by Affymetrix microarray analysis (P \< 0.05).
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###### Additional file 2

**Supplementary experimental procedures**. The file contains supplementing information about the experimental procedures including preparation of TTA stock solution and medium, gene expression experiments and antibodies used.
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